In reversal, FDA panel votes to recommend experimental ALS drug
NBCMAR 28 2022
Between the current unmet needs of ALS patients and Amlyx's promise to withdraw the drug if shown ineffective, this was the right decision by the advisory panel. With no cure for this devastating disease and few other medications on the market, it's only fair that patients be given the chance to try and extend their lives as much as possible.
Though patients and advocates understandably want any and every possible treatment available, the FDA should be skeptical of a drug that hasn't completed its trials and a company's promise to voluntarily withdraw it from the market if it fails in order to receive approval. There's a reason it was declined in the past.